Ulcerative colitis.

@article{Danese2011UlcerativeC,
  title={Ulcerative colitis.},
  author={S. Danese and C. Fiocchi},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 18},
  pages={
          1713-25
        }
}
 Is medical clearance required? .................................. Possibly (e.g., if the disease is unstable — flare-up — and/or there are active oral lesions). Also, medical clearance may be required if patient/client is being treated with medications associated with immunosuppression +/increased risk of infection (e.g., corticosteroids [e.g., prednisone], azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, sulfasalazine, biologic response modifier drugs [e.g., anti-tumour necrosis… Expand
Biological Agents for Moderately to Severely Active Ulcerative Colitis
Immunosuppressive and biologic therapy for ulcerative colitis
Skin Manifestations of Inflammatory Bowel Disease
Ulcerative Colitis: Update on Medical Management
Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists
  • B. Feagan, D. Rubin, +5 authors M. Smyth
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2017
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
Colectomy rate in acute severe ulcerative colitis in the infliximab era.
  • A. Aratari, C. Papi, +5 authors R. Caprilli
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2008
Update on the etiology, pathogenesis and diagnosis of ulcerative colitis
  • S. Hanauer
  • Medicine
  • Nature Clinical Practice Gastroenterology &Hepatology
  • 2004
...
1
2
3
4
5
...